IXHL — Incannex Healthcare Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1873875 · Australia
Last close
$3.36
Market Cap
$40.20M
52W High
$6.46
52W Low
$2.49
ADV30
375,295
Next earnings
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -3,966,000 -3,883,000 80,283,000 74,450,000 5,049,000
Dec 2025 0 -6,513,000 -6,521,000 75,006,000 68,900,000 1,600,000
Sep 2025 0 -6,405,000 -6,407,000 78,720,000 73,280,000 1,712,000
Mar 2025 0 -4,582,000 -3,968,000 16,197,000 6,711,000 8,794,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-22,571,000
Investing CF
$-54,000
Financing CF
$79,898,000
CapEx
$-6,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-17.10
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-170,484,000
Inventory
Receivables
$5,299,000
ST Investments
EBIT TTM
$-22,485,000
Pretax Income TTM
$-22,790,000
Interest Exp TTM
$303,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-24,695,000
Free Cash Flow
$-8,271,875
Enterprise Value
$-32,220,770
Total Cash
$74,450,000
Total Debt
$114,000
Shares Out
11,964,554
Trailing EPS
$-16.62
Book Value
$5.50
ROE
-117.2%
ROA
-32.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jun 2025
Jun 2024 12,000 -18,607,000 -18,459,000 17,047,000 5,830,000 -15,845,000
Jun 2023 0 -13,638,000 -48,811,000 23,783,000 2,958,000 -10,749,000
Jun 2022 0 -10,164,241 -10,252,538 26,057,735 1,383,064 -8,810,311

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.96

Peers — same industry

TickerNameMarket CapLastDaily %
KALA KALA BIO, Inc. $40.34M $2.17
ZYBT Zhengye Biotechnology Holding Ltd $40.75M $0.86
MIRA MIRA PHARMACEUTICALS, INC. $40.93M $0.97
RNXT RenovoRx, Inc. $41.30M $0.92
TLPH TALPHERA, INC. $41.52M $0.80

News headlines (Yahoo Finance, 1h cache)

Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
2026-05-14 14:35 · Yahoo
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
2026-05-12 12:00 · Yahoo
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
2026-04-22 12:00 · Yahoo
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
2026-03-27 12:00 · Yahoo
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
2026-03-25 12:00 · Yahoo
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
2026-03-18 12:00 · Yahoo
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-03-17 12:00 · Yahoo
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2026-03-12 12:05 · Yahoo
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes
2026-03-12 12:00 · Yahoo
Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26
2026-03-03 20:24 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.